Halozyme Therapeutics (NASDAQ:HALO) PT Lowered to $71.00 at JMP Securities

Halozyme Therapeutics (NASDAQ:HALO) had its price target lowered by JMP Securities from $72.00 to $71.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “market outperform” rating on the biopharmaceutical company’s stock. JMP Securities’ price target points to a potential upside of 61.95% from the company’s current price.

Other analysts also recently issued reports about the company. The Goldman Sachs Group lowered their price target on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research report on Thursday, January 18th. TheStreet downgraded Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. TD Cowen began coverage on Halozyme Therapeutics in a research report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price target for the company. Benchmark restated a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, April 16th. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.14.

Halozyme Therapeutics Stock Up 4.4 %

NASDAQ HALO opened at $43.84 on Wednesday. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64. The company has a market capitalization of $5.57 billion, a P/E ratio of 20.78, a P/E/G ratio of 0.47 and a beta of 1.26. Halozyme Therapeutics has a one year low of $31.05 and a one year high of $45.00. The stock has a 50 day moving average price of $40.17 and a 200-day moving average price of $38.05.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The firm had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. As a group, equities analysts predict that Halozyme Therapeutics will post 3.43 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total transaction of $384,900.00. Following the completion of the sale, the senior vice president now directly owns 168,176 shares in the company, valued at $6,473,094.24. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders sold 30,000 shares of company stock worth $1,196,800. 2.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Halozyme Therapeutics by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 13,259,514 shares of the biopharmaceutical company’s stock valued at $490,072,000 after buying an additional 152,870 shares during the period. Artisan Partners Limited Partnership increased its stake in shares of Halozyme Therapeutics by 3.4% during the third quarter. Artisan Partners Limited Partnership now owns 7,712,874 shares of the biopharmaceutical company’s stock valued at $294,632,000 after buying an additional 253,363 shares during the period. TD Asset Management Inc grew its stake in Halozyme Therapeutics by 28.1% in the first quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock valued at $103,379,000 after purchasing an additional 557,350 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Halozyme Therapeutics by 2.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,736,122 shares of the biopharmaceutical company’s stock valued at $64,167,000 after purchasing an additional 37,763 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Halozyme Therapeutics by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,613,113 shares of the biopharmaceutical company’s stock valued at $59,622,000 after purchasing an additional 145,879 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.